ST-920, Emerging Drug Insight and Market Forecast - 2032

“ST-920, Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about ST-920 for Fabry Disease in the 7MM. A detailed picture of the ST-920 for Fabry Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the ST-920 for Fabry Disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ST-920 market forecast, analysis for Fabry Disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Fabry Disease.

Drug Summary

ST-920 (isaralgagene civaparvovecis) is a gene therapy that comprises an AAV vector carrying a GLA gene construct driven by a proprietary liver-specific promoter. It is designed to enable a patient's liver to produce a long-lasting and continuous supply of the α-Gal A enzyme.

Preclinical studies of ST-920 showed a positive response, and one-time administration in mice led to substantial increases in the activity of the enzyme α-Gal A and marked reductions in the levels of the fatty molecules that accumulate in patients with this disease. Based on a positive response, the FDA accepted the IND application of the gene therapy for the treatment of the FD, and the company initiated the Phase I/II clinical study of the product for the treatment of FD. ST-920 was generally well tolerated in Phase I/II. Based on this data, Sangamo Therapeutics plans a phase III trial for Fabry's disease in the second half of 2022.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ST-920 description, mechanism of action, dosage and administration, research and development activities in Fabry Disease.
• Elaborated details on ST-920 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ST-920 research and development activity in Fabry Disease in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ST-920.
• The report contains forecasted sales of ST-920 for Fabry Disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Fabry Disease.
• The report also features the SWOT analysis with analyst views for ST-920 in Fabry Disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ST-920 Analytical Perspective

In-depth ST-920 Market Assessment

This report provides a detailed market assessment of ST-920 in Fabry Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for the ST-920.

ST-920 Clinical Assessment

The report provides the clinical trials information of ST-920 in Fabry Disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Fabry Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ST-920dominance.
• Other emerging products for Fabry Disease are expected to give tough market competition to ST-920 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ST-920 in Fabry Disease.
• Our in-depth analysis of the forecasted sales data of ST-920 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ST-920 in Fabry Disease.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ST-920?
• What is the clinical trial status of the study related to ST-920 in Fabry Disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ST-920 development?
• What are the key designations that have been granted to ST-920 for Fabry Disease?
• What is the forecasted market scenario of ST-920 for Fabry Disease?
• What are the forecasted sales of ST-920 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Fabry Disease and how are they giving competition to ST-920 for Fabry Disease?
• Which are the late-stage emerging therapies under development for the treatment of Fabry Disease?